by Mark Curtis | Nov 20, 2014
. You have all by now heard that Dendreon has filed for bankruptcy protection. If you’re a regular reader of Signals, you may have first heard the news here. While the company has successfully reached agreements on a financial restructuring with a majority of its...
by Sara M. Nolte | Sep 29, 2014
> It’s September again! That means new grad students in the lab, seminars and courses start again, committee meetings, grant deadlines, product shows, and… Journal Club. What is Journal Club – and why am I about to spend an entire post talking about it? Ideally, it...
by David Brindley | Sep 23, 2014
. With contributions from James Smith, a recent Oxford University graduate and current SENS Research Foundation Summer Scholar working at the Harvard Stem Cell Institute. Assume a single bacterium weighs one thousand billionth of a gram. If it, and each of its...
by Mark Curtis | Sep 18, 2014
. Welcome to your Update from the Clinic for the month of August. Asterias Biotherapeutics breathes new life into a cell therapy shelved two years ago and initiates a Phase I/II study in patients with spinal cord injury. Northwest Biotherapeutics provides an update on...
by Mark Curtis | Sep 11, 2014
. Welcome to your deal review for the month of August. As would be expected at the end of the summer news flow was modest, but Northwest Biotherapeutics kept things alive with a $17.5 million financing via convertible debt, while Gamida Cell announced a game-changing...
Comments